JP2019509330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509330A5 JP2019509330A5 JP2018558113A JP2018558113A JP2019509330A5 JP 2019509330 A5 JP2019509330 A5 JP 2019509330A5 JP 2018558113 A JP2018558113 A JP 2018558113A JP 2018558113 A JP2018558113 A JP 2018558113A JP 2019509330 A5 JP2019509330 A5 JP 2019509330A5
- Authority
- JP
- Japan
- Prior art keywords
- alpha
- dermatological composition
- composition
- permeation
- adrenergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 88
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 28
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical group CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 22
- 239000000464 adrenergic agent Substances 0.000 claims description 19
- 210000000744 eyelid Anatomy 0.000 claims description 15
- 239000003961 penetration enhancing agent Substances 0.000 claims description 15
- 229960001528 oxymetazoline Drugs 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims description 4
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000014121 butter Nutrition 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 239000000516 sunscreening agent Substances 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 201000003004 ptosis Diseases 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical compound CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 210000002468 fat body Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 238000013270 controlled release Methods 0.000 description 15
- -1 silazoline Chemical compound 0.000 description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 6
- OQFCXJDXHCDLHX-UHFFFAOYSA-N N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide Chemical compound C1CCC=2C(NS(=O)(=O)C)=C(O)C=CC=2C1C1=NCCN1 OQFCXJDXHCDLHX-UHFFFAOYSA-N 0.000 description 6
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 4
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 3
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 3
- SQVIAVUSQAWMKL-UHFFFAOYSA-N 3-[2-(ethylamino)-1-hydroxyethyl]phenol Chemical compound CCNCC(O)C1=CC=CC(O)=C1 SQVIAVUSQAWMKL-UHFFFAOYSA-N 0.000 description 3
- SBUQBFTXTZSRMH-UHFFFAOYSA-N 4-(2-amino-1-hydroxyethyl)-5-fluorobenzene-1,2-diol Chemical compound NCC(O)C1=CC(O)=C(O)C=C1F SBUQBFTXTZSRMH-UHFFFAOYSA-N 0.000 description 3
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 3
- CMVHOLZLFLESKY-UHFFFAOYSA-N Anisodine Natural products CN1C2CC(CC1C3OC23)C(=O)OC(O)(CO)c4ccccc4 CMVHOLZLFLESKY-UHFFFAOYSA-N 0.000 description 3
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 3
- XFDVJGKSQRUEEM-UHFFFAOYSA-N N-(2,6-Dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine Chemical compound ClC1=CC(CN(CCCl)C)=CC(Cl)=C1NC1=NCCN1 XFDVJGKSQRUEEM-UHFFFAOYSA-N 0.000 description 3
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 3
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 3
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 3
- JEJREKXHLFEVHN-QDXGGTILSA-N anisodine Chemical compound C1([C@](O)(CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 JEJREKXHLFEVHN-QDXGGTILSA-N 0.000 description 3
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 3
- 229940127070 chloroethylclonidine Drugs 0.000 description 3
- 229950008484 corbadrine Drugs 0.000 description 3
- 229960001623 desvenlafaxine Drugs 0.000 description 3
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 3
- 229960000966 dipivefrine Drugs 0.000 description 3
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 description 3
- 229960002267 ethylnorepinephrine Drugs 0.000 description 3
- PNHJTLDBYZVCGW-UHFFFAOYSA-N indanidine Chemical compound C=1C=CC2=NN(C)C=C2C=1NC1=NCCN1 PNHJTLDBYZVCGW-UHFFFAOYSA-N 0.000 description 3
- 229950003924 indanidine Drugs 0.000 description 3
- 229960005192 methoxamine Drugs 0.000 description 3
- 229960001094 midodrine Drugs 0.000 description 3
- 229960005016 naphazoline Drugs 0.000 description 3
- 229960001576 octopamine Drugs 0.000 description 3
- 229960003684 oxedrine Drugs 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- 229960000395 phenylpropanolamine Drugs 0.000 description 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 3
- 229960003908 pseudoephedrine Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 3
- 229960000833 xylometazoline Drugs 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical class CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010224A JP2022058765A (ja) | 2016-01-26 | 2022-01-26 | アルファアドレナリン作動薬の組成物および使用 |
| JP2024025657A JP2024057010A (ja) | 2016-01-26 | 2024-02-22 | アルファアドレナリン作動薬の組成物および使用 |
| JP2025162838A JP2026001122A (ja) | 2016-01-26 | 2025-09-30 | アルファアドレナリン作動薬の組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287391P | 2016-01-26 | 2016-01-26 | |
| US62/287,391 | 2016-01-26 | ||
| PCT/US2017/015181 WO2017132410A1 (en) | 2016-01-26 | 2017-01-26 | Compositions and uses of alpha-adrenergic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010224A Division JP2022058765A (ja) | 2016-01-26 | 2022-01-26 | アルファアドレナリン作動薬の組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509330A JP2019509330A (ja) | 2019-04-04 |
| JP2019509330A5 true JP2019509330A5 (https=) | 2020-03-05 |
Family
ID=59398678
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558113A Withdrawn JP2019509330A (ja) | 2016-01-26 | 2017-01-26 | アルファアドレナリン作動薬の組成物および使用 |
| JP2022010224A Pending JP2022058765A (ja) | 2016-01-26 | 2022-01-26 | アルファアドレナリン作動薬の組成物および使用 |
| JP2024025657A Pending JP2024057010A (ja) | 2016-01-26 | 2024-02-22 | アルファアドレナリン作動薬の組成物および使用 |
| JP2025162838A Pending JP2026001122A (ja) | 2016-01-26 | 2025-09-30 | アルファアドレナリン作動薬の組成物および使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010224A Pending JP2022058765A (ja) | 2016-01-26 | 2022-01-26 | アルファアドレナリン作動薬の組成物および使用 |
| JP2024025657A Pending JP2024057010A (ja) | 2016-01-26 | 2024-02-22 | アルファアドレナリン作動薬の組成物および使用 |
| JP2025162838A Pending JP2026001122A (ja) | 2016-01-26 | 2025-09-30 | アルファアドレナリン作動薬の組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10828252B2 (https=) |
| EP (1) | EP3407976A4 (https=) |
| JP (4) | JP2019509330A (https=) |
| CN (2) | CN108883308A (https=) |
| AU (3) | AU2017211793B2 (https=) |
| WO (1) | WO2017132410A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| CN108883308A (zh) | 2016-01-26 | 2018-11-23 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
| FI3541362T3 (fi) | 2016-11-15 | 2026-02-05 | Klaria Pharma Holding Ab | Triptaania käsittävä alginaattikalvo |
| EP3595515A4 (en) | 2017-03-14 | 2020-12-30 | University of Connecticut | BIODEGRADABLE PRESSURE SENSOR |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| EP3759213B1 (en) | 2018-03-02 | 2026-04-29 | Quantumcyte, Inc. | Methods, compositions, and devices for isolation and expression analysis of regions of interest from a tissue |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2020100142A1 (en) * | 2018-11-15 | 2020-05-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lactide containing polyester-polyethylene glycol triblock thermoresponsive copolymers |
| US11826495B2 (en) | 2019-03-01 | 2023-11-28 | University Of Connecticut | Biodegradable piezoelectric ultrasonic transducer system |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| US11745001B2 (en) | 2020-03-10 | 2023-09-05 | University Of Connecticut | Therapeutic bandage |
| US12491290B2 (en) | 2020-06-08 | 2025-12-09 | University Of Connecticut | Biodegradable piezoelectric composite materials |
| CN112791033A (zh) * | 2020-12-30 | 2021-05-14 | 广东蕾琪化妆品有限公司 | 一种新型眼影及其制备方法 |
| US20240225978A1 (en) * | 2021-01-23 | 2024-07-11 | Christine Lynn Bokman | Methods and compositions for pharmacological treatment of blepharoptosis |
| CN113149022B (zh) * | 2021-04-30 | 2022-07-22 | 南昌大学 | 一种二氧化硅@硅酸钙中空纳米球及其制备方法和应用 |
| US11779553B1 (en) * | 2022-11-28 | 2023-10-10 | Atif B. D. Collins | Methods and devices for treatment of eyelid ptosis |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2784127A (en) | 1954-06-02 | 1957-03-05 | Eastman Kodak Co | Plasticized monomeric adhesive compositions and articles prepared therefrom |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
| US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
| US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
| US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| US4444933A (en) | 1982-12-02 | 1984-04-24 | Borden, Inc. | Adhesive cyanoacrylate compositions with reduced adhesion to skin |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| AU673160B2 (en) | 1992-02-28 | 1996-10-31 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US5654381A (en) | 1995-06-16 | 1997-08-05 | Massachusetts Institute Of Technology | Functionalized polyester graft copolymers |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| US5628863A (en) | 1996-06-12 | 1997-05-13 | Lee; Shu-Ken | Pouch producing machine |
| US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| KR20050092429A (ko) * | 2003-01-22 | 2005-09-21 | 니찌방 가부시기가이샤 | 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법 |
| US7776915B2 (en) * | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| US20090136598A1 (en) * | 2006-04-26 | 2009-05-28 | Aciex, Inc. | Compositions for the Treatment and Prevention of Eyelid Swelling |
| CA2650592A1 (en) * | 2006-04-26 | 2007-11-08 | Aciex, Inc. | Compositions for the treatment and prevention of eyelid swelling |
| JP2010535591A (ja) | 2007-08-06 | 2010-11-25 | トランスダーム， インコーポレイテッド | ポリマー膜から形成される微小針アレイ |
| WO2009061431A2 (en) * | 2007-11-08 | 2009-05-14 | Aciex Therapeutics, Inc. | Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor |
| WO2010118340A1 (en) * | 2009-04-09 | 2010-10-14 | University Of Medicine And Dentistry Of New Jersey | Treatment of cutaneous hemangioma |
| US9034830B2 (en) * | 2009-10-30 | 2015-05-19 | Intratus, Inc. | Methods and compositions for sustained delivery of drugs |
| US8883838B2 (en) | 2010-12-03 | 2014-11-11 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| RU2014104559A (ru) | 2011-07-14 | 2015-08-20 | Аллерган, Инк. | Гелевые композиции оксиметазолина и способы их применения |
| US20130035338A1 (en) * | 2011-08-05 | 2013-02-07 | Gordon Tang | Eyelid treatment |
| SG11201405643RA (en) | 2012-03-16 | 2014-10-30 | Univ Singapore | A novel method to fabricate polymeric microneedles |
| EP2866607A4 (en) | 2012-06-29 | 2016-07-13 | Elc Man Llc | SOLUBLE MICROARRAYS COMPRISING ONE OR MORE ENCAPSULATED COSMETIC INGREDIENTS |
| AU2015274532B2 (en) | 2014-06-11 | 2020-06-11 | Epi Health, Llc | Stabilized oxymetazoline formulations and their uses |
| US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CN108883308A (zh) | 2016-01-26 | 2018-11-23 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
-
2017
- 2017-01-26 CN CN201780020181.6A patent/CN108883308A/zh active Pending
- 2017-01-26 EP EP17744911.3A patent/EP3407976A4/en active Pending
- 2017-01-26 WO PCT/US2017/015181 patent/WO2017132410A1/en not_active Ceased
- 2017-01-26 JP JP2018558113A patent/JP2019509330A/ja not_active Withdrawn
- 2017-01-26 AU AU2017211793A patent/AU2017211793B2/en active Active
- 2017-01-26 CN CN202210425295.1A patent/CN115006537A/zh active Pending
-
2018
- 2018-07-24 US US16/043,725 patent/US10828252B2/en active Active
-
2020
- 2020-10-02 US US17/061,869 patent/US11311476B2/en active Active
- 2020-10-06 US US17/064,327 patent/US11491104B2/en active Active
-
2022
- 2022-01-26 JP JP2022010224A patent/JP2022058765A/ja active Pending
- 2022-09-21 US US17/933,929 patent/US12357561B2/en active Active
- 2022-10-24 AU AU2022257242A patent/AU2022257242A1/en not_active Abandoned
-
2024
- 2024-01-09 AU AU2024200121A patent/AU2024200121B2/en active Active
- 2024-02-22 JP JP2024025657A patent/JP2024057010A/ja active Pending
-
2025
- 2025-06-17 US US19/240,606 patent/US20260034050A1/en active Pending
- 2025-09-30 JP JP2025162838A patent/JP2026001122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509330A5 (https=) | ||
| EP3733192B1 (en) | Finasteride formulations for drug release to hair and scalp | |
| NZ578611A (en) | Dermal film-forming liquid formulations for drug release to skin | |
| KR102754277B1 (ko) | 블랙헤드를 치료하기 위한 조성물 및 방법 | |
| AU3211999A (en) | An acidified composition for topical treatment of nail and skin conditions | |
| HRP20140397T1 (hr) | Spojevi, formulacije i metode za smanjivanje boranja, mreškanja i opuštanja kože | |
| EP2493309A1 (en) | Methods of treating or preventing acute erythema | |
| WO2007098591A2 (en) | Topical nail formulation | |
| JP2013538853A (ja) | 酒瘡の併用による治療 | |
| CN110652658A (zh) | 使用光和葡糖胺盐酸盐处理皮肤病症的组合物和方法 | |
| JP5832302B2 (ja) | ケラチンへの局所薬剤デリバリーにおける表面活性タンパク質の組成物、使用及び使用方法 | |
| EP3089751B1 (fr) | Composition topique comprenant des extraits de boldo et de reine des pres, destinee a un animal, et ses applications | |
| US20170095466A1 (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| EP3334433A1 (fr) | Composition antidouleur comprenant un derive de l'acide salicylique | |
| MX2014004383A (es) | Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5. | |
| KR20180122324A (ko) | 피부 자극에 영향을 미치는 조성물 및 방법 | |
| EP3991734B1 (en) | Agent for the treatment of alopecia and promoting hair growth | |
| RU2573976C2 (ru) | Применение по новому назначению бензилбензоата в качестве антигрибкового средства, получение и применение антимикозных фармацевтических композиций | |
| CN103189041A (zh) | 手指甲或脚趾甲生长促进用组合物 | |
| US20210177740A1 (en) | Transpore delivery of cannabinoid and uses thereof | |
| EA045149B1 (ru) | Средство для усиления роста волос | |
| AU2003246031A1 (en) | An acidified composition for topical treatment of nail and skin conditions |